Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapy
MPR may be a novel pathologic end point in HR+/HER2-breast cancer after neoadjuvant chemotherapy, holding greater applicability in the prognosis evaluation than pCR.
Authors
- Fei Ma (ORCID: https://orcid.org/0000-0001-9432-1902)
- Xiaoyan Qian (ORCID: https://orcid.org/0000-0001-7509-8071)
- Min Xiao (ORCID: https://orcid.org/0000-0001-9421-6344)
- Lei Ji (ORCID: https://orcid.org/0000-0001-8391-9300)
- Qing Li (ORCID: https://orcid.org/0009-0000-4993-8372)
- Xi Chen (ORCID: https://orcid.org/0000-0003-3855-2591)
- Jiayu Wang (ORCID: https://orcid.org/0000-0003-0470-0322)
- Shanshan Chen (ORCID: https://orcid.org/0000-0001-9723-2403)
- Binghe Xu (ORCID: https://orcid.org/0000-0002-0234-2747)
- Pin Zhang (ORCID: https://orcid.org/0000-0001-8903-3666)
- Qiao Li (ORCID: https://orcid.org/0000-0002-9714-198X)
- Ying Fan (ORCID: https://orcid.org/0000-0003-3419-9399)
- Yang Luo (ORCID: https://orcid.org/0000-0001-5387-3954)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
Publication Details
- Journal
- The Breast
- Published
- 2024-08-30
- DOI
- https://doi.org/10.1016/j.breast.2024.103792
- Citations
- 3
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.86